Drug Type Small molecule drug |
Synonyms GSK 690693, GSK690693 |
Action inhibitors |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT1 inhibitors), Akt-2 inhibitors(Serine/threonine-protein kinase AKT2 inhibitors), Akt-3 inhibitors(Serine/threonine-protein kinase AKT3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H27N7O3 |
InChIKeyKGPGFQWBCSZGEL-ZDUSSCGKSA-N |
CAS Registry937174-76-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Phase 1 | - | 01 Apr 2008 | |
Lymphoma | Phase 1 | United States | 01 Apr 2007 | |
Malignant Solid Neoplasm | Phase 1 | United States | 01 Apr 2007 | |
Mucoepidermoid Carcinoma | Preclinical | United States | 01 Jul 2017 |